Release issued 24th June 2008

Multikinase inhibitors, most notably Pfizer's Sutent, will continue to dominate the market, according to a new report from Decision Resources

June 24, 2008, Waltham, Mass.  Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the Renal Cell Carcinoma drug market will more than double over the next 10 years, rising from US$ 625 million in 2007 to nearly US$ 1.6 billion in 2017. Market growth will continue to be driven by the dominance of the multikinase inhibitors drug class, most notably Pfizer's Sutent.

According to the new Pharmacor report entitled Renal Cell Carcinoma, Sutent will maintain its position as the leading therapy for the disease and will capture US$ 841 million in sales in 2017 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The report finds that multikinase inhibitors, which comprised 92 percent of the Renal Cell Carcinoma drug market in 2007, will capture nearly three quarters of the market in 2017.

The report also finds that three emerging targeted therapies-GlaxoSmithKline's Armala, Pfizer's Axitinib and Novartis's Everolimus-will launch over the next decade and will achieve significant uptake in the second-line patient segment through 2017. Additionally, although there are no treatments that have, to date, shown efficacy in the adjuvant setting in nonmetastatic Renal Cell Carcinoma patients, the results of clinical trials underway in this patient segment could further drive market growth.

"The most notable trial currently underway, the Adjuvant Sorafenib or Sunitinib in Unfavorable Renal Cell Carcinoma Trial, is comparing the efficacy of Sutent versus Bayer Healthcare/Onyx's Nexavar versus placebo in extending disease-free survival in the adjuvant setting," said Ramya Kollipara, Ph.D., analyst at Decision Resources. "If these drugs are approved for treatment in the adjuvant setting, their use in this setting will be a major driver of growth in the Renal Cell Carcinoma market over the next decade."

About Decision Resources
Decision Resources, Inc. (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

(9th September 2008) Glaxo SmithKline’s Lamictal will continue to dominate the epilepsy drug market over the next 10 years

(9th September 2008) Robust sales of Integrilin, Reopro and Aggrastat will drive the

(9th September 2008) Novel oral anticoagulants, particularly Bayer/Ortho-Mcneil’s Xarelto,

(8th September 2008) China’s Hepatitis C virus drug market will grow to $150 million by 2012

(4th September 2008) Physicians eager to increase their first- and second-line prescriptions for Januvia over the next two years for the treatment of type 2 Diabetes